Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Huangdai tablet plus imatinib vs placebo plus imatinib in chronic-phase Ph+ CML
CTR20170221Phase 3Active
- Sponsor
- Anhui Tiankang Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Compound Huangdai Tablet in chronic myelogenous leukemia (CML), sponsored by Anhui Tiankang Pharmaceutical. Started Mar 2017; status: active.
02
Drugs
Compound Huangdai Tablet
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20170221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170221.